Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NVCR)

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Business Wire 3 days ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Business Wire 3 days ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Business Wire October 30, 2024

Novocure Reports Third Quarter 2024 Financial Results

Business Wire October 30, 2024

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Business Wire October 15, 2024

Novocure to Report Third Quarter 2024 Financial Results

Business Wire October 1, 2024

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Business Wire September 9, 2024

Novocure Announces Planned CEO Transition

Business Wire September 3, 2024

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

Business Wire August 28, 2024
View More News ››

Opinion & Analysis (NDAQ:NVCR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NVCR)

FDA Approves Novocure's Optune Lua&#xAE; for the Treatment o

Just In: $NVCR FDA Approves Novocure's Optune Lua&#xAE; for the Treatment of Metastatic Non-Small Cell Lung CancerThe first...
whytestocks - October 15, 2024

Novocure to Participate in 2024 Wells Fargo Healthcare Confe

Breaking News: $NVCR Novocure to Participate in 2024 Wells Fargo Healthcare ConferenceNovocure (NASDAQ: NVCR) announced today that...
whytestocks - August 28, 2024

Why NovoCure Stock Is Crashing Today

NEWS: $NVCR Why NovoCure Stock Is Crashing Today2023-06-06 11:50:17 ET Shares of NovoCure (NASDAQ: NVCR) were crashing 29.6% lower as of...
whytestocks - June 6, 2023
View more Bullboard ››

Lithium Ionic Corp

Lithium Ionic Corp

Lithium Ionic Corp. is a Canadian mining company. The Company is engaged exploring and developing its lithium properties in ...
View More »